<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DENAVIR- penciclovir cream </strong><br>New American Therapeutics, Inc<br></p></div>
<h1>
<span class="Bold">Denavir<span class="Sup">®</span></span><br><span class="Bold">BRAND OF</span><br><span class="Bold">penciclovir cream, 1%</span><br><br><span class="Bold">For Dermatologic Use Only</span><br><span class="Bold">Rx only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-1"></a><p></p>
<h1>
Prescribing Information
</h1>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-2"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First"><span class="Italics">Denavir</span> (penciclovir) cream 1% contains penciclovir, an antiviral agent active against herpes viruses. <span class="Italics">Denavir</span> is available for topical administration as a 1% white cream. Each gram of <span class="Italics">Denavir</span> contains 10 mg of penciclovir and the following inactive ingredients: cetomacrogol 1000 BP, cetostearyl alcohol, mineral oil, propylene glycol, purified water and white petrolatum.</p>
<p>Chemically, penciclovir is known as 9-[4-hydroxy-3-(hydroxymethyl)butyl]guanine. Its molecular formula is C<span class="Sub">10</span>H<span class="Sub">15</span>N<span class="Sub">5</span>O<span class="Sub">3</span>; its molecular weight is 253.26. It is a synthetic acyclic guanine derivative and has the following structure:</p>
<div class="Figure"><img alt="
denavir-01
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d119057-f299-43ea-b516-e84a09cab890&amp;name=denavir-01.jpg"></div>
<p>Penciclovir is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow solid. At 20°C it has a solubility of 0.2 mg/mL in methanol, 1.3 mg/mL in propylene glycol, and 1.7 mg/mL in water. In aqueous buffer (pH 2) the solubility is 10.0 mg/mL.</p>
<p>Penciclovir is not hygroscopic. Its partition coefficient in n-octanol/water at pH 7.5 is 0.024 (logP = -1.62).
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-3"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-3.1"></a><p></p>
<h2>
Microbiology
</h2>
<p class="First"><span class="Bold">Mechanism of Antiviral Activity:</span> The antiviral compound penciclovir has <span class="Italics">in vitro</span> inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, viral thymidine kinase phosphorylates penciclovir to a monophosphate form which, in turn, is converted to penciclovir triphosphate by cellular kinases. <span class="Italics">In vitro</span> studies demonstrate that penciclovir triphosphate inhibits HSV polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited.</p>
<p><br><span class="Bold">Antiviral Activity </span><span class="Bold Italics">In Vitro</span><span class="Bold"> and </span><span class="Bold Italics">In Vivo</span><span class="Bold">:</span> In cell culture studies, penciclovir has antiviral activity against HSV-1 and HSV-2. Sensitivity test results, expressed as the concentration of the drug required to inhibit growth of the virus by 50% (IC<span class="Sub">50</span>) or 99% (IC<span class="Sub">99</span>) in cell culture, vary depending upon a number of factors, including the assay protocols. See Table 1.</p>
<table width="80%">
<caption><span>
Table 1
</span></caption>
<col align="left" width="30%">
<col align="center" width="19%">
<col align="center" width="17%">
<col align="center" width="17%">
<col align="center" width="17%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">
Method of Assay
</th>
<th class="Lrule Rrule" align="center">
Virus Type
</th>
<th class="Lrule Rrule" align="center">
Cell Type
</th>
<th class="Lrule Rrule" align="center">
IC<span class="Sub">50</span> (mcg/mL)
</th>
<th class="Lrule Rrule" align="center">
IC<span class="Sub">99</span> (mcg/mL)
</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="5">
(c.i.) = clinical isolates. The latent state of any herpes virus is not known to respond to any viral therapy.
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">
Plaque Reduction
</td>
<td class="Lrule Rrule" align="center">
HSV-1 (c.i.)
</td>
<td class="Lrule Rrule" align="center">
MRC-5
</td>
<td class="Lrule Rrule" align="center">
0.2-0.6
</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Lrule Rrule" align="center">
HSV-1 (c.i.)
</td>
<td class="Lrule Rrule" align="center">
WISH
</td>
<td class="Lrule Rrule" align="center">
0.04-0.5
</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Lrule Rrule" align="center">
HSV-2 (c.i.)
</td>
<td class="Lrule Rrule" align="center">
MRC-5
</td>
<td class="Lrule Rrule" align="center">
0.9-2.1
</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Lrule Rrule" align="center">
HSV-2 (c.i.)
</td>
<td class="Lrule Rrule" align="center">
WISH
</td>
<td class="Lrule Rrule" align="center">
0.1-0.8
</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
Virus Yield Reduction
</td>
<td class="Lrule Rrule" align="center">
HSV-1 (c.i.)
</td>
<td class="Lrule Rrule" align="center">
MRC-5
</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">
0.4-0.5
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Lrule Rrule" align="center">
HSV-2 (c.i.)
</td>
<td class="Lrule Rrule" align="center">
MRC-5
</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">
0.6-0.7
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
DNA Synthesis Inhibition
</td>
<td class="Lrule Rrule" align="center">
HSV-1 (SC16)
</td>
<td class="Lrule Rrule" align="center">
MRC-5
</td>
<td class="Lrule Rrule" align="center">
0.04
</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"></td>
<td class="Lrule Rrule" align="center">
HSV-2 (MS.)
</td>
<td class="Lrule Rrule" align="center">
MRC-5
</td>
<td class="Lrule Rrule" align="center">
0.05
</td>
<td class="Lrule Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span>:</span> Penciclovir-resistant mutants of HSV can result from qualitative changes in viral thymidine kinase or DNA polymerase. The most commonly encountered acyclovir-resistant mutants that are deficient in viral thymidine kinase are also resistant to penciclovir.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-3.2"></a><p></p>
<h2>
Pharmacokinetics
</h2>
<p class="First">Measurable penciclovir concentrations were not detected in plasma or urine of healthy male volunteers (n=12) following single or repeat application of the 1% cream at a dose of 180 mg penciclovir daily (approximately 67 times the estimated usual clinical dose).</p>
<p><span class="Bold">Pediatric Patients:</span> The systemic absorption of penciclovir following topical administration has not been evaluated in patients &lt;18 years of age.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionClinicalStudies"></a><a name="section-4"></a><p></p>
<h1>
CLINICAL TRIALS
</h1>
<p class="First"><span class="Italics">Denavir</span> was studied in two double-blind, placebo (vehicle)-controlled trials for the treatment of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> in which otherwise healthy adults were randomized to either <span class="Italics">Denavir</span> or placebo. Therapy was to be initiated by the subjects within 1 hour of noticing signs or symptoms and continued for 4 days, with application of study medication every 2 hours while awake. In both studies, the mean duration of lesions was approximately one-half-day shorter in the subjects treated with <span class="Italics">Denavir</span> (N=1,516) as compared to subjects treated with placebo (N=1,541) (approximately 4.5 days versus 5 days, respectively). The mean duration of lesion <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was also approximately one half-day shorter in the <span class="Italics">Denavir</span> group compared to the placebo group.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-5"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Italics">Denavir</span> (penciclovir cream) is indicated for the treatment of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>) in adults and children 12 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-6"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<p class="First"><span class="Italics">Denavir</span> is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product or any of its components.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-7"></a><p></p>
<h1>
PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-7.1"></a><p></p>
<h2>
General
</h2>
<p class="First"><span class="Italics">Denavir</span> should only be used on <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> on the lips and face. Because no data are available, application to human mucous membranes is not recommended. Particular care should be taken to avoid application in or near the eyes since it may cause irritation. Lesions that do not improve or that worsen on therapy should be evaluated for secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>. The effect of <span class="Italics">Denavir</span> has not been established in immunocompromised patients.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-7.2"></a><p></p>
<h2>
Information for Patients
</h2>
<p class="First"><span class="Italics">Denavir</span> is a prescription topical cream for the treatment of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> (recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>) that occur on the face and lips. It is not a cure for <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span> and not all patients respond to it. Do not use if you are allergic to <span class="Italics">Denavir</span> (penciclovir) or any of the ingredients in <span class="Italics">Denavir</span> cream. Before you use <span class="Italics">Denavir</span>, tell your doctor if you are pregnant, planning to become pregnant, or are breast-feeding.</p>
<p><span class="Bold">Directions:</span> Wash your hands. Your face should be clean and dry. Apply a layer of <span class="Italics">Denavir</span> cream to cover only the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore area or the area of <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> (or other symptoms) before the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore appears. Rub in the cream until it disappears. Apply the cream every 2 hours during waking hours for 4 days. Even though <span class="Italics">Denavir</span> works at the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> stage, treatment should be started at the earliest sign of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sore (i.e., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or bump). Wash your hands with soap and water after using <span class="Italics">Denavir</span> cream. Store <span class="Italics">Denavir</span> cream at room temperature (59°-86°F). Keep out of reach of children.</p>
<p><span class="Bold">Possible side effects:</span><span class="Italics">Denavir</span> cream was well tolerated in clinical studies in patients with <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>. The most frequently reported side effect was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Common skin-related side effects of <span class="Italics">Denavir</span> cream are <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>, local anesthesia, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-7.3"></a><p></p>
<h2>
Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">In clinical trials, systemic drug exposure following the topical administration of penciclovir cream was negligible, as the penciclovir content of all plasma and urine samples was below the limit of assay detection (0.1 mcg/mL and 10 mcg/mL, respectively). However, for the purpose of inter-species dose comparisons presented in the following sections, an assumption of 100% absorption of penciclovir from the topically applied product has been used. Based on use of the maximal recommended topical dose of penciclovir of 0.05 mg/kg/day and an assumption of 100% absorption, the maximum theoretical plasma AUC<span class="Sub">0-24</span> hrs for penciclovir is approximately 0.129 mcg.hr/mL.</p>
<p><br><span class="Bold Italics">Carcinogenesis:</span> Two-year carcinogenicity studies were conducted with famciclovir (the oral prodrug of penciclovir) in rats and mice. An increase in the incidence of mammary adenocarcinoma (a common tumor in female rats of the <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> used) was seen in female rats receiving 600 mg/kg/day (approximately 395× the maximum theoretical human exposure to penciclovir following application of the topical product, based on area under the plasma concentration curve comparisons [24 hr. AUC]). No increases in tumor incidence were seen among male rats treated at doses up to 240 mg/kg/day (approximately 190× the maximum theoretical human AUC for penciclovir), or in male and female mice at doses up to 600 mg/kg/day (approximately 100× the maximum theoretical human AUC for penciclovir).</p>
<p><br><span class="Bold Italics">Mutagenesis:</span> When tested <span class="Italics">in vitro</span>, penciclovir did not cause an increase in gene mutation in the Ames assay using multiple <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">S. typhimurium</span> or <span class="Italics">E. coli</span> (at up to 20,000 mcg/plate), nor did it cause an increase in unscheduled DNA repair in mammalian HeLa S3 cells (at up to 5,000 mcg/mL). However, an increase in clastogenic responses was seen with penciclovir in the L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell assay (at doses ≥1000 mcg/mL) and, in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> incubated <span class="Italics">in vitro</span> at doses ≥250 mcg/mL. When tested <span class="Italics">in vivo</span>, penciclovir caused an increase in micronuclei in mouse bone marrow following the intravenous administration of doses ≥500 mg/kg (≥810× the maximum human dose, based on body surface area conversion).</p>
<p><br><span class="Bold Italics">Impairment of Fertility:</span> Testicular toxicity was observed in multiple animal species (rats and dogs) following repeated intravenous administration of penciclovir (160 mg/kg/day and 100 mg/kg/day, respectively, approximately 1155 and 3255× the maximum theoretical human AUC). Testicular changes seen in both species included <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the seminiferous tubules and reductions in epididymal sperm counts and/or an increased incidence of sperm with abnormal morphology or reduced motility. Adverse testicular effects were related to an increasing dose or duration of exposure to penciclovir. No adverse testicular or reproductive effects (fertility and reproductive function) were observed in rats after 10 to 13 weeks dosing at 80 mg/kg/day, or testicular effects in dogs after 13 weeks dosing at 30 mg/kg/day (575 and 845× the maximum theoretical human AUC, respectively). Intravenously administered penciclovir had no effect on fertility or reproductive performance in female rats at doses of up to 80 mg/kg/day (260× the maximum human dose [BSA]).</p>
<p>There was no evidence of any clinically significant effects on sperm count, motility or morphology in 2 placebo-controlled clinical trials of Famvir<span class="Sup">®</span> (famciclovir [the oral prodrug of penciclovir], 250 mg b.i.d.; n=66) in immunocompetent men with recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, when dosing and follow-up were maintained for 18 and 8 weeks, respectively (approximately 2 and 1 spermatogenic cycles in the human).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-7.4"></a><p></p>
<h2>
Pregnancy
</h2>
<p class="First"><span class="Bold">Teratogenic Effects-Pregnancy Category B.</span> No adverse effects on the course and outcome of pregnancy or on fetal development were noted in rats and rabbits following the intravenous administration of penciclovir at doses of 80 and 60 mg/kg/day, respectively (estimated human equivalent doses of 13 and 18 mg/kg/day for the rat and rabbit, respectively, based on body surface area conversion; the body surface area doses being 260 and 355× the maximum recommended dose following topical application of the penciclovir cream). There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, penciclovir should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-7.5"></a><p></p>
<h2>
Nursing Mothers
</h2>
<p class="First">There is no information on whether penciclovir is excreted in human milk after topical administration. However, following oral administration of famciclovir (the oral prodrug of penciclovir) to lactating rats, penciclovir was excreted in breast milk at concentrations higher than those seen in the plasma. Therefore, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>There are no data on the safety of penciclovir in newborns.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-7.6"></a><p></p>
<h2>
Pediatric Use
</h2>
<p class="First">An open-label, uncontrolled trial with penciclovir cream 1% was conducted in 102 patients, ages 12-17 years, with recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>. The frequency of adverse events was generally similar to the frequency previously reported for adult patients. Safety and effectiveness in pediatric patients less than 12 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-7.7"></a><p></p>
<h2>
Geriatric Use
</h2>
<p class="First">In 74 patients ≥65 years of age, the adverse events profile was comparable to that observed in younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-8"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<p class="First">In two double-blind, placebo-controlled trials, 1516 patients were treated with <span class="Italics">Denavir</span> (penciclovir cream) and 1541 with placebo. The most frequently reported adverse event was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, which occurred in 5.3% of the patients treated with <span class="Italics">Denavir</span> and 5.8% of the placebo-treated patients. The rates of reported local adverse reactions are shown in Table 2 below. One or more local adverse reactions were reported by 2.7% of the patients treated with <span class="Italics">Denavir</span> and 3.9% of placebo-treated patients.</p>
<table width="80%">
<caption><span>
Table 2 - Local Adverse Reactions Reported in Phase III Trials
</span></caption>
<col align="left" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
<thead><tr class="Botrule First Last Toprule">
<th class="Rrule" align="center"></th>
<th class="Lrule Rrule Toprule" align="center">
Penciclovir<br>n=1516<br>%
</th>
<th class="Lrule Rrule Toprule" align="center">
Placebo<br>N=1541<br>%
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">
Applications site reaction
</td>
<td class="Lrule Rrule" align="center">
1.3
</td>
<td class="Lrule Rrule" align="center">
1.8
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypesthesia</span>/Local anesthesia
</td>
<td class="Lrule Rrule" align="center">
0.9
</td>
<td class="Lrule Rrule" align="center">
1.4
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span>
</td>
<td class="Lrule Rrule" align="center">
0.2
</td>
<td class="Lrule Rrule" align="center">
0.3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>
</td>
<td class="Lrule Rrule" align="center">
0.0
</td>
<td class="Lrule Rrule" align="center">
0.3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td class="Lrule Rrule" align="center">
0.0
</td>
<td class="Lrule Rrule" align="center">
0.1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (erythematous)
</td>
<td class="Lrule Rrule" align="center">
0.1
</td>
<td class="Lrule Rrule" align="center">
0.1
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>
</td>
<td class="Lrule Rrule" align="center">
0.0
</td>
<td class="Lrule Rrule" align="center">
0.1
</td>
</tr>
</tbody>
</table>
<p>Two studies, enrolling 108 healthy subjects, were conducted to evaluate the dermal tolerance of 5% penciclovir cream (a 5-fold higher concentration than the commercial formulation) compared to vehicle using repeated occluded patch testing methodology. The 5% penciclovir cream induced mild <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> in approximately one-half of the subjects exposed, an irritancy profile similar to the vehicle control in terms of severity and proportion of subjects with a response. No evidence of sensitization was observed.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection4"></a><a name="section-8.1"></a><p></p>
<h2>
Post-Marketing Experience
</h2>
<p class="First">The following events have been identified from worldwide post-marketing use of <span class="Italics">Denavir</span> in treatment of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> (<span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>) in adults. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to <span class="Italics">Denavir</span> cream.</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, oral/<span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>.</p>
<p><span class="Bold">Skin:</span> <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span>, aggravated condition, decreased therapeutic response, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, local <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-9"></a><p></p>
<h1>
OVERDOSAGE
</h1>
<p class="First">Since penciclovir is poorly absorbed following oral administration, adverse reactions related to penciclovir ingestion are unlikely. There is no information on <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-10"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION
</h1>
<p class="First"><span class="Italics">Denavir</span> should be applied every 2 hours during waking hours for a period of 4 days. Treatment should be started as early as possible (i.e., during the prodrome or when lesions appear).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-11"></a><p></p>
<h1>
HOW SUPPLIED
</h1>
<p class="First">Denavir is supplied in a 1.5 gram and 5 gram tube containing 10 mg of penciclovir per gram.</p>
<p>NDC 50816-624-01</p>
<p>NDC 50816-624-05</p>
<p>Store at controlled room temperature, 20°-25°C (68°-77°F) [see USP]</p>
<p><br><span class="Bold">QUESTIONS?</span> call <span class="Bold">1-866-736-8798</span></p>
<p><br>October 2011</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-12"></a><p></p>
<p class="First">Manufactured for <span class="Bold">New American Therapeutics, Inc.</span><br>Roseland, NJ 07068<br>by Novartis Pharma GmbH, Wehr, Germany<br><span class="Bold">Denavir®</span> is licensed to <span class="Bold">New American Therapeutics, Inc.</span> from <span class="Bold">Denco Asset, LLC.</span></p>
<p><span class="Bold">©2010 New American Therapeutics, Inc.</span><br>US 908697<br>262F401- 2074542
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-13"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL
</h1>
<p class="First">NDC 50816-624-05</p>
<p>Denavir<span class="Sup">®</span><br>(penciclovir cream) 1%</p>
<p>5 g (Net Wt.)</p>
<p>For Topical Use Only</p>
<div class="Figure"><img alt="
denavir-02
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d119057-f299-43ea-b516-e84a09cab890&amp;name=denavir-02.jpg"></div>
<p> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DENAVIR 		
					</strong><br><span class="contentTableReg">penciclovir cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50816-624</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PENCICLOVIR</strong> (PENCICLOVIR) </td>
<td class="formItem">PENCICLOVIR</td>
<td class="formItem">10 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CETETH-20</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETOSTEARYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50816-624-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50816-624-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020629</td>
<td class="formItem">12/29/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>New American Therapeutics, Inc
							(962163734)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Denco Asset, LLC (965099505)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novartis Pharma Produktions GmbH</td>
<td class="formItem"></td>
<td class="formItem">333288046</td>
<td class="formItem">manufacture</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novartis Grimsby Ltd</td>
<td class="formItem"></td>
<td class="formItem">212245609</td>
<td class="formItem">api manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3a3aa611-f531-489a-99c7-2fbad3b04f86</div>
<div>Set id: 8d119057-f299-43ea-b516-e84a09cab890</div>
<div>Version: 3</div>
<div>Effective Time: 20111005</div>
</div>
</div> <div class="DistributorName">New American Therapeutics, Inc</div></p>
</body></html>
